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Abstract
have attended pain clinics. Moreover, 20% of the chronic pain that patients suffer is neuropathic. There-
existing literature on this syndrome that has been published in recent years. Moreover, a complementary 
objective of this article is to create an approach to localized neuropathic pain by focusing on its pathophy-
siology, diagnosis, and treatment, which can be pharmacological (e.g. lidocaine and capsaicin in topical 
perspectives about the study of localized neuropathic pain.
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1. Introduction
According to the International Association for the 
Study of Pain (IASP), pain is ”an unpleasant sen-
sory and emotional experience associated with ac-
tual or potential tissue damage, or described in ter-
ms of such damage” (1). Its purpose is to warn the 
organism. Meanwhile, neuropathic pain (NP) is a 
as “pain arising as a direct consequence of a lesion 
or disease affecting the somatosensory system” (2). 
It can have a central origin (caused by spinal cord 
or brain damage) or a peripheral origin (caused by 
peripheral nerve damage), and it can be localized (if 
patients, so that treatments can be adapted as speci-
between NP and nociceptive pain.
A group of pain experts met in 2010 to create the 
characterized by consistent and circumscribed area(s) 
-
existing treatments to each patient, depending on the 
type of pain that they suffer and its location (3). 
NP incidence was estimated between 6.9%-10% of 
the population (6). However, there is a lack of stu-
dies specifying the prevalence of each type of NP. It 
is important to highlight that 20% of chronic pain is 
neuropathic (7). Therefore, it is essential to diagno-
quality of life. According to the Guide for Diagnostic 
and Therapeutic Pharmacological Approach of Lo-
calized Peripheral Neuropathic Pain (4), a study ca-
rried out with patients treated in pain clinics showed 
and had a greater prevalence of peripheral NP, con-
siderably higher than in other European countries. 
As reported by a survey conducted among doctors, 
the prevalence of LNP in their patients suffering NP 
lidocaine (8, 9), capsaicin (10, 11), clonidine, and bo-
tulinum toxin type A (BTX-A) for topical treatment 
(12, 13). The purpose of this article is to carry out 
a review of the existing literature on LNP and to 
explore the pathophysiology, diagnosis, and treat-
ment of this syndrome.
NP is caused by a lesion or a disease which affects 
the somatosensory system (12). Such lesion or in-
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adaptive changes in the nervous system that pro-
duce pain due to sensitization. This process acts as 
a protective mechanism to ensure the adequate hea-
ling of the tissues. In NP, changes in sensitization 
are persistent, causing spontaneous pain with a low 
stimulus threshold and even an onset or an increase 
of the pain with non-painful stimuli. This produces 
maladaptive changes on sensory neurons that can 
be irreversible (7, 14).
Some of the physiological changes that are pro-
duced in the peripheral area are electrical hyperex-
citability and abnormal impulses (ectopic electroge-
primary sensory neurons in the dorsal root ganglion 
neurons and abnormal responses to mechanical, 
thermal, and chemical stimuli in many other neu-
rons. The remodeling of voltage-sensitive ion chan-
nels, transducer molecules, and receptors in the cell 
membrane seems to be the cellular mechanism that 
-
ponsibility because they are directly involved in the 
-
te in the membrane of injured nerve areas and in 
demyelination areas, the synthesis of the subtypes 
is increased, and its individual contribution could 
be increased by the mediators of hyperalgesia. In 
addition, this leads to a downregulation and to the 
block of K+ channels. The ectopic discharge contri-
butes to NP as it generates a direct afferent signal 
and it can trigger and maintain central sensitization 
-
ciceptors, the presence of ephapses, and abnormal 
of the posterior horn are sensitized and descending 
pain inhibitory mechanisms are altered (7).
LNP is also characterized by peripheral hype-
rexcitability, with overexpression of sodium and 
TRPV family 1 channels, which are located on ner-
ve cell membranes. The analgesic effect of topical 
drugs used for NP treatment is particularly related 
to such channels, which are widely distributed on 
NP syndrome occurs as a complex combination 
of symptoms with interindividual variance that de-
pends on the underlying pathophysiological chan-
ges resulting from the convergence of multiple etio-
logical, genotypic, and environmental factors (7).
NP can present negative signs (e.g. sensory loss) 
or positive signs (e.g. abnormal neurosensorial res-
ponses). Somatization and sleep problems are also 
common, as well as mental disorders such as anxie-
in determining that the somatosensory system is 
damaged. Positive signs can be either spontaneous 
(e.g. spontaneous pain, dysesthesia, paraesthesia) 
or evoked (e.g. allodynia, hyperalgesia, hyperpa-
thia) (7). Table 2 shows the most relevant medical 
signs.
NP and LNP follow the same diagnosis. According 
to authors such as Finnerup et al. (17) and the IASP 
(1), if a patient suffers from a pain that could be the 
result of a neurologic lesion or disease instead of a 
-
3.1. Possible neuropathic pain
searching for a neurologic disease or lesion. The 
health record must show the pain history, suffered 
diseases, and existing comorbidities. In order to 
determine the pain level suffered by the patient, a 
visual analogue scale or a numerical scale can be 
used (18), as well as other scales or questionnaires 
(17, 19). Electrophysiological techniques such as 
electromyography (EMG), nerve conduction study 
-
sical examination is advisable to locate the painful 
area (18). In order for a patient to be diagnosed with 
possible LNP, two criteria must be met: (1) the po-
tential existence of a serious neurologic problem 
(e.g. ictus, diabetic neuropathy) must be checked, 
and (2) the anatomical location of the pain must 
be determined in order to decide if it is compatible 
with the location of the lesion in the central or pe-
ripheral somatosensory nervous system (17). Pain 
can appear immediately or insidiously, depending 
on the lesion or disease, and the time relationship is 
relevant for the diagnosis (17).
3.2. Probable neuropathic pain
In this case, enough clinical support is needed to 
the existence of positive signs, negative signs will 
determine LNP diagnosis (17). Table 3 shows posi-
tive and negative signs of NP.
In order for a patient to be diagnosed with pro-
bable LNP, the following scales and questionnaires 
must be positive: the LANSS scale, the Neuropathic 
Pain Questionnaire, the DN4 questionnaire, pain-
DETECT or ID-Pain (17). Currently, there is a new 
enables to determine the localized character of NP 
(4) and which must also be positive to ascertain that 
NP is probable.
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The diagnosis must be based on medical imaging 
techniques which describe the lesion in the soma-
tosensory nervous system, including: magnetic 
resonance imaging (MRI), computed tomography 
(CT) scan (17), neurophysiological tests (e.g. EMG, 
nerve conduction) (4), evoked potentials, quantita-
among others. It should be noted that there can be 
other pain causes, and experts may not know if the-
re is a direct causality (17). Figure 1 shows a diag-
nostic algorithm facing NP.
4. Treatment
Pharmacological treatment for chronic illnesses has 
the disadvantage of a long-term low compliance by 
patients with the treatment. In addition, the effec-
tiveness of pharmacological treatment for NP is 
limited, and only 40% of the patients experience a 
capsaicin (3).
4.1.1. 5% lidocaine
present a pharmacological action through lidocai-
ne and a protective action by means of the patch, 
which acts as a physical barrier before the stimuli 
causing hyperalgesia (21). Lidocaine carries out a 
non-selective blockade of Na+ channels, and it at-
-
ged. This blockade halts signal propagation. Never-
and the binding rate of the drug, since there is not 
a complete sensory blockade of Na+ channels (21). 
Lidocaine patches reduce allodynia and NP symp-
toms (3).
The half-life of lidocaine is 7.6 hours. Therefo-
re, it must be administered every 24 hours to keep 
its analgesic effect (16). The most common adverse 
effects of lidocaine are erythema, burning sensa-
tion, rashes, edema, and dermatitis, and they are 
limited to the application area (16).
4.1.2. 8% capsaicin
When neuropathy is caused by post-herpetic neu-
-
rus (HIV), capsaicin patches have been given the 
Neurological Sciences (16). Capsaicin interacts with 
-
action is mediated by the opening of the TRPV1 
channel and the subsequent depolarization throu-
gh Na+ and Ca2+, as well as Ca2+ liberation to the 
endoplasmic reticulum (22). The high concentration 
of Ca2+ blocks the afferent nerves selectively. No-
ciceptive pain symptoms improvement occurs be-
tween 6 and 12 weeks by using a single 8% capsai-
cin patch (23). The drug effects last up to 90 days, so 
it is administered every three months (16).
4.1.3. Other topical and non-topical targeted 
treatments
Several topical targeted treatments for LNP are not 
yet commercially available. One of them is ketami-
ne, an N-Methyl-D-aspartic acid (NMDA) receptor 
agonist that reduces the threshold of nerve trans-
duction and central sensitization (16). Ketamine is 
not approved for LNP treatment, although its effec-
tiveness has been demonstrated (3).
Dextromethorphan is a non-competitive NMDA 
receptor antagonist, marketed as an external patch 
whose function is to relieve both muscular and 
rheumatic pain (16). Another example is bupiva-
caine, which is a local anaesthetic that blocks Na+ 
channels, also marketed as a long acting patch that 
provides an anaesthetic effect for a period of up to 
3 days after a single application. Its effect is com-
diclofenac and ketoprofen are nonsteroidal anti-in-
and creams to treat chronic pain (24). In addition, 
-
tial -agonist buprenorphine has not been tested in 
LNP, although its effectiveness has been demons-
trated in chronic cancer cases and non-cancer pain 
(3).
On the other hand, oral antidepressants and an-
tiepileptics are also recommended for LNP treat-
ment. Although there are numerous antidepressant 
and antiepileptic drugs, rotigotine and amitriptyli-
ne are the only ones that have been evaluated to 
treat pain conditions. The most commonly used an-
tiepileptic drugs in LNP treatment are gabapentin 
and pregabalin, both administered orally (24).
capsaicin patch are the only topical dressings that 
As of today, there is little evidence of the use 
of non-pharmacological treatment for LNP. Howe-
ver, the few existing data recommend its use as an 
attempt to reduce the use of medications and im-
163
Archivos de Medicina Universitaria | Vol. 1, núm. 1
4.2.1. Interventional therapies
Spinal cord stimulation is a low-intensity electri-
modulates the pain signals from non-myelinated 
neuromodulation strategy, but also the most resear-
ched. It is based on the application of a monophasic 
square-wave pulse, which causes paresthesia in the 
affected region. New types of stimulation, such as 
burst and high frequency stimulation, can produ-
ce a stimulation without paresthesia and an equal 
pain relief compared with the monophasic squa-
re-wave pulse. These techniques are relatively safe, 
and their long-term effectiveness has been demons-
trated by randomized controlled trials and several 
cases (26).
Dorsal root ganglion intervention, peripheral 
-
mulation are three therapies based on the neuros-
and the subcutaneous stimulation of the peripheral 
nerve area. A cohort research reported that stimu-
Epidural motor cortex stimulation (EMCS), re-
petitive transcranial magnetic stimulation (rTMS), 
and transcranial direct current stimulation (tDCS) 
of central motor cortex at levels below the motor 
threshold (27) can reduce thalamus hyperactivity 
or activate descending inhibitory pathways. Data 
appear to indicate that 60% of patients respond to 
EMCS (28).
Moreover, the internal capsule, nuclei in the sen-
sory thalamus, the periaqueductal gray substance, 
the motor cortex, the septum, the accumbens, the 
posterior hypothalamus, and the anterior cingulate 
cortex have been suggested as potential target areas 
in deep brain stimulation. However, the application 
-
cant risks showed by the current evidence (26).
4.2.2. Physical therapies
Although there is little evidence of the effectiveness 
of physical therapy, there are signs indicating that 
physical exercise and movement representation te-
chniques (i.e. treatments that use the observation or 
imagination of normal pain-free movements, like 
(29).
4.2.3. Psychological therapies
The main goal of these therapies is to promote pain 
management and to reduce its emotional conse-
quences. Cognitive-behavioral therapy (CBT), who-
se purpose is to lead the patient to an “individual 
change”, is the most researched therapy. This treat-
ment addresses mood, function (including disabili-
ty) social engagement, and analgesia as an indirect 
target. There are not enough evidences of the effec-
tiveness of these therapies in LNP treatment, so an 
5. Discussion and future perspectives
Nowadays, we face multiple challenges in relation 
to LNP. It is very hard to make a correct diagnosis of 
-
nition. Although there are several debates going on 
-
could be useful against the different types of NP (3), 
since there are patients with a treatment that does 
not effectively adjust to their pathology. Further re-
search on the pathophysiological characteristics of 
LNP could help in the development of new effecti-
In conclusion, an in-depth study of LNP is re-
quired in order to increase our knowledge about it, 
focusing on three aspects: (1) a global consensus on 
and (3) more research on the effective treatments 
for each type of NP.
These aspects could enhance the adequacy of 
treatments, improving their effectiveness and pa-
condition. 
-
terest in this article.
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Annex I: Tables
Table 1: Differences between neuropathic pain and nociceptive pain, a relevant distinction in order to 
provide an effective diagnosis.
Adapted from: Torres, LM et al. (2017) (4)
Table 2: Most relevant medical signs of neuropathic pain.
Adapted from: Velasco, M (2014) (7)
Table 3:
between localized neuropathic pain and nociceptive pain.
Adapted from: Correa-Illanes G. (2014) (20)
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 Diagnostic algorithm for localized neuropathic pain.
Adapted from: Martínez-Salió, A. et al. (2009) (19)
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